#METABOLOMICS WORKBENCH kuppal2_20190625_115502 DATATRACK_ID:1844 STUDY_ID:ST001423 ANALYSIS_ID:AN002380 PROJECT_ID:000000 VERSION 1 CREATED_ON July 10, 2020, 4:44 pm #PROJECT PR:PROJECT_TITLE Aspirin Metabolomics in Colorectal Cancer Chemoprevention - Blood PR:PROJECT_TYPE NIH/NCI R01CA188038 PR:PROJECT_SUMMARY Substantial evidence supports the effectiveness of aspirin for cancer PR:PROJECT_SUMMARY chemoprevention in addition to its well established role in cardiovascular PR:PROJECT_SUMMARY protection. In recent meta-analyses of randomized controlled trials in human, PR:PROJECT_SUMMARY daily aspirin use reduced incidence, metastasis and mortality from several PR:PROJECT_SUMMARY common types of cancer, especially colorectal cancer. The mechanism(s) by which PR:PROJECT_SUMMARY aspirin exerts an anticancer benefit is uncertain; numerous effects have been PR:PROJECT_SUMMARY described involving both cyclooxygenase-dependent and -independent pathways. The PR:PROJECT_SUMMARY goal of this research is to elucidate the key metabolic changes that are PR:PROJECT_SUMMARY responsible for the anticancer effects of aspirin in humans using untargeted PR:PROJECT_SUMMARY metabolomics analysis. Metabolomics, or global metabolite profiling, is an PR:PROJECT_SUMMARY emerging discipline that has the potential to transform the study of PR:PROJECT_SUMMARY pharmaceutical agents. Our innovative approach will use high-resolution mass PR:PROJECT_SUMMARY spectroscopy to detect thousands of metabolites in blood plasma and normal colon PR:PROJECT_SUMMARY mucosa biopsies that were collected from participants in the Aspirin/Folate PR:PROJECT_SUMMARY Polyp Prevention Study, a randomized, double-blind, placebo-controlled trial of PR:PROJECT_SUMMARY aspirin and/or folic acid supplementation for the prevention of colorectal PR:PROJECT_SUMMARY adenomas. Participants in the trial were assigned with equal probability to PR:PROJECT_SUMMARY three aspirin treatment arms (placebo, 81mg, or 325mg daily). Over the PR:PROJECT_SUMMARY three-year period, 81mg/day of aspirin reduced the risk of adenomas, whereas the PR:PROJECT_SUMMARY 325 mg/day dose had less effect. The aims of the current proposal are to PR:PROJECT_SUMMARY identify metabolomic signatures, including specific metabolites and metabolic PR:PROJECT_SUMMARY pathways, that are associated with aspirin treatment in blood and normal colon PR:PROJECT_SUMMARY mucosal tissue of participants after three years of randomized aspirin PR:PROJECT_SUMMARY treatment; and then to assess the associations of these metabolic signatures PR:PROJECT_SUMMARY with adenoma risk and whether they mediate the reductions in risk due to 81 PR:PROJECT_SUMMARY mg/day aspirin treatment. We will prioritize metabolites for study by evaluating PR:PROJECT_SUMMARY metabolite levels in patients from the placebo and treatment arms while PR:PROJECT_SUMMARY controlling the false discovery rate, use correlation analysis to enhance PR:PROJECT_SUMMARY identification of relevant metabolic modules associated with these prioritized PR:PROJECT_SUMMARY metabolites, and apply pathway mapping with post-hoc application of ion PR:PROJECT_SUMMARY dissociation spectroscopy to representative metabolites to confirm pathway PR:PROJECT_SUMMARY identification. Because aspirin is a multifunctional drug that is thought to PR:PROJECT_SUMMARY modify numerous pathways with potential roles in carcinogenesis, a global PR:PROJECT_SUMMARY discovery-based metabolomics approach is the best way to identify its key PR:PROJECT_SUMMARY activities. The public health significance of this work is substantial because PR:PROJECT_SUMMARY understanding the mechanism of aspirin's anticancer effects is key to optimizing PR:PROJECT_SUMMARY its use and to the development of novel drugs targeting the metabolic pathways PR:PROJECT_SUMMARY identified. PR:INSTITUTE Emory University Dept of Medicine PR:DEPARTMENT School of Medicine PR:LABORATORY Clinical Biomarkers Laboratory PR:LAST_NAME Tran PR:FIRST_NAME ViLinh PR:ADDRESS 615 Michael St, suite 225 PR:EMAIL vtran6@emory.edu PR:PHONE 4047275091 PR:FUNDING_SOURCE NIH/NCI R01CA188038 #STUDY ST:STUDY_TITLE Aspirin Metabolomics in Colorectal Cancer Chemoprevention - blood (part-II) ST:STUDY_SUMMARY Substantial evidence supports the effectiveness of aspirin for cancer ST:STUDY_SUMMARY chemoprevention in addition to its well established role in cardiovascular ST:STUDY_SUMMARY protection. In recent meta-analyses of randomized controlled trials in human, ST:STUDY_SUMMARY daily aspirin use reduced incidence, metastasis and mortality from several ST:STUDY_SUMMARY common types of cancer, especially colorectal cancer. The mechanism(s) by which ST:STUDY_SUMMARY aspirin exerts an anticancer benefit is uncertain; numerous effects have been ST:STUDY_SUMMARY described involving both cyclooxygenase-dependent and -independent pathways. The ST:STUDY_SUMMARY goal of this research is to elucidate the key metabolic changes that are ST:STUDY_SUMMARY responsible for the anticancer effects of aspirin in humans using untargeted ST:STUDY_SUMMARY metabolomics analysis. Metabolomics, or global metabolite profiling, is an ST:STUDY_SUMMARY emerging discipline that has the potential to transform the study of ST:STUDY_SUMMARY pharmaceutical agents. Our innovative approach will use high-resolution mass ST:STUDY_SUMMARY spectroscopy to detect thousands of metabolites in blood plasma that were ST:STUDY_SUMMARY collected from participants in the Aspirin/Folate Polyp Prevention Study, a ST:STUDY_SUMMARY randomized, double-blind, placebo-controlled trial of aspirin for the prevention ST:STUDY_SUMMARY of colorectal adenomas. Participants in the trial were assigned with equal ST:STUDY_SUMMARY probability to three aspirin treatment arms (placebo, 81mg, or 325mg daily). ST:STUDY_SUMMARY Over the three-year period, 81mg/day of aspirin reduced the risk of adenomas, ST:STUDY_SUMMARY whereas the 325 mg/day dose had less effect. The aims of the current proposal ST:STUDY_SUMMARY are to identify metabolomic signatures, including specific metabolites and ST:STUDY_SUMMARY metabolic pathways, that are associated with aspirin treatment in blood after ST:STUDY_SUMMARY three years of randomized aspirin treatment; and then to assess the associations ST:STUDY_SUMMARY of these metabolic signatures with adenoma risk and whether they mediate the ST:STUDY_SUMMARY reductions in risk due to 81 mg/day aspirin treatment. We will prioritize ST:STUDY_SUMMARY metabolites for study by evaluating metabolite levels in patients from the ST:STUDY_SUMMARY placebo and treatment arms while controlling the false discovery rate, use ST:STUDY_SUMMARY correlation analysis to enhance identification of relevant metabolic modules ST:STUDY_SUMMARY associated with these prioritized metabolites, and apply pathway mapping with ST:STUDY_SUMMARY post-hoc application of ion dissociation spectroscopy to representative ST:STUDY_SUMMARY metabolites to confirm pathway identification. Because aspirin is a ST:STUDY_SUMMARY multifunctional drug that is thought to modify numerous pathways with potential ST:STUDY_SUMMARY roles in carcinogenesis, a global discovery-based metabolomics approach is the ST:STUDY_SUMMARY best way to identify its key activities. The public health significance of this ST:STUDY_SUMMARY work is substantial because understanding the mechanism of aspirin's anticancer ST:STUDY_SUMMARY effects is key to optimizing its use and to the development of novel drugs ST:STUDY_SUMMARY targeting the metabolic pathways identified. ST:INSTITUTE Emory University ST:DEPARTMENT School of Medicine ST:LABORATORY Clincal Biomarkers Laboratory ST:LAST_NAME Uppal ST:FIRST_NAME Karan ST:ADDRESS 615 Michael St, Suite 225 ST:EMAIL kuppal2@emory.edu ST:PHONE (404) 727 5027 ST:TOTAL_SUBJECTS 446 ST:STUDY_COMMENTS Aspirin Metabolomics Priority 2 #SUBJECT SU:SUBJECT_TYPE Human SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 SU:AGE_OR_AGE_RANGE 29-82 SU:GENDER Male and female #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS Quality Control nist_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160715_M198_001 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_1a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160715_M198_007 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_1b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160715_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000207_1 Sex:F | Treatment:325mg SampleID=70905; RAW_FILE_NAME=VT_160715_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000208_1 Sex:F | Treatment:325mg SampleID=70905; RAW_FILE_NAME=VT_160715_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000342_1 Sex:M | Treatment:81mg SampleID=40564; RAW_FILE_NAME=VT_160715_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000344_1 Sex:M | Treatment:81mg SampleID=40564; RAW_FILE_NAME=VT_160715_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000493_1 Sex:F | Treatment:placebo SampleID=21798; RAW_FILE_NAME=VT_160715_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005703_1 Sex:F | Treatment:placebo SampleID=21798; RAW_FILE_NAME=VT_160715_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105639_1 Sex:M | Treatment:placebo SampleID=60566; RAW_FILE_NAME=VT_160715_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006424_1 Sex:M | Treatment:placebo SampleID=60566; RAW_FILE_NAME=VT_160715_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105795_1 Sex:F | Treatment:325mg SampleID=50958; RAW_FILE_NAME=VT_160715_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105794_1 Sex:F | Treatment:325mg SampleID=50958; RAW_FILE_NAME=VT_160715_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105931_1 Sex:M | Treatment:81mg SampleID=21732; RAW_FILE_NAME=VT_160715_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105932_1 Sex:M | Treatment:81mg SampleID=21732; RAW_FILE_NAME=VT_160715_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106527_1 Sex:F | Treatment:placebo SampleID=50409; RAW_FILE_NAME=VT_160715_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006194_1 Sex:F | Treatment:placebo SampleID=50409; RAW_FILE_NAME=VT_160715_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106702_1 Sex:M | Treatment:325mg SampleID=10539; RAW_FILE_NAME=VT_160715_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000794_1 Sex:M | Treatment:325mg SampleID=10539; RAW_FILE_NAME=VT_160715_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106759_1 Sex:M | Treatment:placebo SampleID=10976; RAW_FILE_NAME=VT_160715_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005391_1 Sex:M | Treatment:placebo SampleID=10976; RAW_FILE_NAME=VT_160715_M198_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000266_1 Sex:M | Treatment:placebo SampleID=80298; RAW_FILE_NAME=VT_160715_M198_127 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000267_1 Sex:M | Treatment:placebo SampleID=80298; RAW_FILE_NAME=VT_160715_M198_133 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_1c_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160715_M198_139 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_2a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160716_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000321_1 Sex:M | Treatment:placebo SampleID=21058; RAW_FILE_NAME=VT_160716_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000322_1 Sex:M | Treatment:placebo SampleID=21058; RAW_FILE_NAME=VT_160716_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000351_1 Sex:F | Treatment:placebo SampleID=40632; RAW_FILE_NAME=VT_160716_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005994_1 Sex:F | Treatment:placebo SampleID=40632; RAW_FILE_NAME=VT_160716_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105590_1 Sex:F | Treatment:81mg SampleID=30473; RAW_FILE_NAME=VT_160716_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105591_1 Sex:F | Treatment:81mg SampleID=30473; RAW_FILE_NAME=VT_160716_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105652_1 Sex:M | Treatment:325mg SampleID=60667; RAW_FILE_NAME=VT_160716_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006241_1 Sex:M | Treatment:325mg SampleID=60667; RAW_FILE_NAME=VT_160716_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105802_1 Sex:M | Treatment:placebo SampleID=51017; RAW_FILE_NAME=VT_160716_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105803_1 Sex:M | Treatment:placebo SampleID=51017; RAW_FILE_NAME=VT_160716_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105939_1 Sex:M | Treatment:325mg SampleID=80366; RAW_FILE_NAME=VT_160716_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006462_1 Sex:M | Treatment:325mg SampleID=80366; RAW_FILE_NAME=VT_160716_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106545_1 Sex:F | Treatment:325mg SampleID=91335; RAW_FILE_NAME=VT_160716_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007108_1 Sex:F | Treatment:325mg SampleID=91335; RAW_FILE_NAME=VT_160716_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106736_1 Sex:F | Treatment:81mg SampleID=10796; RAW_FILE_NAME=VT_160716_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015435_1 Sex:F | Treatment:81mg SampleID=10796; RAW_FILE_NAME=VT_160716_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106777_1 Sex:M | Treatment:325mg SampleID=11136; RAW_FILE_NAME=VT_160716_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106778_1 Sex:M | Treatment:325mg SampleID=11136; RAW_FILE_NAME=VT_160716_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000327_1 Sex:M | Treatment:81mg SampleID=21080; RAW_FILE_NAME=VT_160716_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005525_1 Sex:M | Treatment:81mg SampleID=21080; RAW_FILE_NAME=VT_160716_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_2b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160716_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_3a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160717_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000354_1 Sex:M | Treatment:81mg SampleID=40676; RAW_FILE_NAME=VT_160717_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005974_1 Sex:M | Treatment:81mg SampleID=40676; RAW_FILE_NAME=VT_160717_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105615_1 Sex:M | Treatment:325mg SampleID=30664; RAW_FILE_NAME=VT_160717_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105616_1 Sex:M | Treatment:325mg SampleID=30664; RAW_FILE_NAME=VT_160717_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105669_1 Sex:M | Treatment:325mg SampleID=60790; RAW_FILE_NAME=VT_160717_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105670_1 Sex:M | Treatment:325mg SampleID=60790; RAW_FILE_NAME=VT_160717_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105843_1 Sex:M | Treatment:placebo SampleID=51296; RAW_FILE_NAME=VT_160717_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105844_1 Sex:M | Treatment:placebo SampleID=51296; RAW_FILE_NAME=VT_160717_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106127_1 Sex:F | Treatment:placebo SampleID=90626; RAW_FILE_NAME=VT_160717_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106128_1 Sex:F | Treatment:placebo SampleID=90626; RAW_FILE_NAME=VT_160717_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106561_1 Sex:M | Treatment:81mg SampleID=91425; RAW_FILE_NAME=VT_160717_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106562_1 Sex:M | Treatment:81mg SampleID=91425; RAW_FILE_NAME=VT_160717_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106738_1 Sex:M | Treatment:81mg SampleID=10810; RAW_FILE_NAME=VT_160717_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106739_1 Sex:M | Treatment:81mg SampleID=10810; RAW_FILE_NAME=VT_160717_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106809_1 Sex:M | Treatment:placebo SampleID=91000; RAW_FILE_NAME=VT_160717_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006981_1 Sex:M | Treatment:placebo SampleID=91000; RAW_FILE_NAME=VT_160717_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000447_1 Sex:F | Treatment:81mg SampleID=20349; RAW_FILE_NAME=VT_160717_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000448_1 Sex:F | Treatment:81mg SampleID=20349; RAW_FILE_NAME=VT_160717_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105617_1 Sex:M | Treatment:placebo SampleID=30675; RAW_FILE_NAME=VT_160717_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005820_1 Sex:M | Treatment:placebo SampleID=30675; RAW_FILE_NAME=VT_160717_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_3b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160717_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_4a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160718_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000463_1 Sex:F | Treatment:placebo SampleID=20472; RAW_FILE_NAME=VT_160718_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005458_1 Sex:F | Treatment:placebo SampleID=20472; RAW_FILE_NAME=VT_160718_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105687_1 Sex:M | Treatment:placebo SampleID=60926; RAW_FILE_NAME=VT_160718_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105688_1 Sex:M | Treatment:placebo SampleID=60926; RAW_FILE_NAME=VT_160718_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105909_1 Sex:F | Treatment:325mg SampleID=21563; RAW_FILE_NAME=VT_160718_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005670_1 Sex:F | Treatment:325mg SampleID=21563; RAW_FILE_NAME=VT_160718_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106489_1 Sex:F | Treatment:325mg SampleID=50082; RAW_FILE_NAME=VT_160718_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001563_1 Sex:F | Treatment:325mg SampleID=50082; RAW_FILE_NAME=VT_160718_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106628_1 Sex:M | Treatment:81mg SampleID=60656; RAW_FILE_NAME=VT_160718_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015648_1 Sex:M | Treatment:81mg SampleID=60656; RAW_FILE_NAME=VT_160718_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106740_1 Sex:F | Treatment:placebo SampleID=10831; RAW_FILE_NAME=VT_160718_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015255_1 Sex:F | Treatment:placebo SampleID=10831; RAW_FILE_NAME=VT_160718_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106832_1 Sex:F | Treatment:placebo SampleID=91122; RAW_FILE_NAME=VT_160718_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007071_1 Sex:F | Treatment:placebo SampleID=91122; RAW_FILE_NAME=VT_160718_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105749_1 Sex:M | Treatment:placebo SampleID=60296; RAW_FILE_NAME=VT_160718_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006427_1 Sex:M | Treatment:placebo SampleID=60296; RAW_FILE_NAME=VT_160718_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106493_1 Sex:M | Treatment:81mg SampleID=50106; RAW_FILE_NAME=VT_160718_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106494_1 Sex:M | Treatment:81mg SampleID=50106; RAW_FILE_NAME=VT_160718_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106746_1 Sex:M | Treatment:placebo SampleID=80860; RAW_FILE_NAME=VT_160718_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105993_1 Sex:M | Treatment:placebo SampleID=80860; RAW_FILE_NAME=VT_160718_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_4b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160718_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_5a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160720_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106839_1 Sex:F | Treatment:325mg SampleID=91155; RAW_FILE_NAME=VT_160720_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106840_1 Sex:F | Treatment:325mg SampleID=91155; RAW_FILE_NAME=VT_160720_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106293_1 Sex:M | Treatment:81mg SampleID=11439; RAW_FILE_NAME=VT_160720_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005484_1 Sex:M | Treatment:81mg SampleID=11439; RAW_FILE_NAME=VT_160720_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000503_1 Sex:M | Treatment:placebo SampleID=31228; RAW_FILE_NAME=VT_160720_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000504_1 Sex:M | Treatment:placebo SampleID=31228; RAW_FILE_NAME=VT_160720_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000678_1 Sex:F | Treatment:325mg SampleID=50532; RAW_FILE_NAME=VT_160720_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000679_1 Sex:F | Treatment:325mg SampleID=50532; RAW_FILE_NAME=VT_160720_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001758_1 Sex:F | Treatment:placebo SampleID=80792; RAW_FILE_NAME=VT_160720_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001159_1 Sex:F | Treatment:placebo SampleID=80792; RAW_FILE_NAME=VT_160720_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001837_1 Sex:M | Treatment:325mg SampleID=80355; RAW_FILE_NAME=VT_160720_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015939_1 Sex:M | Treatment:325mg SampleID=80355; RAW_FILE_NAME=VT_160720_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001918_1 Sex:M | Treatment:placebo SampleID=90569; RAW_FILE_NAME=VT_160720_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006975_1 Sex:M | Treatment:placebo SampleID=90569; RAW_FILE_NAME=VT_160720_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001971_1 Sex:M | Treatment:325mg SampleID=91010; RAW_FILE_NAME=VT_160720_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006980_1 Sex:M | Treatment:325mg SampleID=91010; RAW_FILE_NAME=VT_160720_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002014_1 Sex:M | Treatment:325mg SampleID=91403; RAW_FILE_NAME=VT_160720_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003308_1 Sex:M | Treatment:325mg SampleID=91403; RAW_FILE_NAME=VT_160720_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106206_1 Sex:M | Treatment:81mg SampleID=41341; RAW_FILE_NAME=VT_160720_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006081_1 Sex:M | Treatment:81mg SampleID=41341; RAW_FILE_NAME=VT_160720_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_5b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160720_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_6a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160721_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106265_1 Sex:M | Treatment:325mg SampleID=11226; RAW_FILE_NAME=VT_160721_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106266_1 Sex:M | Treatment:325mg SampleID=11226; RAW_FILE_NAME=VT_160721_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106354_1 Sex:F | Treatment:placebo SampleID=70300; RAW_FILE_NAME=VT_160721_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001361_1 Sex:F | Treatment:placebo SampleID=70300; RAW_FILE_NAME=VT_160721_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000542_1 Sex:M | Treatment:325mg SampleID=90042; RAW_FILE_NAME=VT_160721_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015916_1 Sex:M | Treatment:325mg SampleID=90042; RAW_FILE_NAME=VT_160721_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000685_1 Sex:M | Treatment:81mg SampleID=50611; RAW_FILE_NAME=VT_160721_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006136_1 Sex:M | Treatment:81mg SampleID=50611; RAW_FILE_NAME=VT_160721_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001792_1 Sex:F | Treatment:81mg SampleID=90187; RAW_FILE_NAME=VT_160721_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006974_1 Sex:F | Treatment:81mg SampleID=90187; RAW_FILE_NAME=VT_160721_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001883_1 Sex:M | Treatment:81mg SampleID=91559; RAW_FILE_NAME=VT_160721_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003096_1 Sex:M | Treatment:81mg SampleID=91559; RAW_FILE_NAME=VT_160721_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001921_1 Sex:M | Treatment:81mg SampleID=90580; RAW_FILE_NAME=VT_160721_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106121_1 Sex:M | Treatment:81mg SampleID=90580; RAW_FILE_NAME=VT_160721_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001973_1 Sex:M | Treatment:81mg SampleID=91021; RAW_FILE_NAME=VT_160721_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106814_1 Sex:M | Treatment:81mg SampleID=91021; RAW_FILE_NAME=VT_160721_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002076_1 Sex:M | Treatment:placebo SampleID=71109; RAW_FILE_NAME=VT_160721_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006672_1 Sex:M | Treatment:placebo SampleID=71109; RAW_FILE_NAME=VT_160721_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106267_1 Sex:M | Treatment:81mg SampleID=11248; RAW_FILE_NAME=VT_160721_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106268_1 Sex:M | Treatment:81mg SampleID=11248; RAW_FILE_NAME=VT_160721_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_6b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160721_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_7a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160722_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106290_1 Sex:M | Treatment:325mg SampleID=11428; RAW_FILE_NAME=VT_160722_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005416_1 Sex:M | Treatment:325mg SampleID=11428; RAW_FILE_NAME=VT_160722_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106404_1 Sex:F | Treatment:325mg SampleID=30811; RAW_FILE_NAME=VT_160722_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005824_1 Sex:F | Treatment:325mg SampleID=30811; RAW_FILE_NAME=VT_160722_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000548_1 Sex:F | Treatment:325mg SampleID=90086; RAW_FILE_NAME=VT_160722_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000549_1 Sex:F | Treatment:325mg SampleID=90086; RAW_FILE_NAME=VT_160722_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000725_1 Sex:M | Treatment:placebo SampleID=50846; RAW_FILE_NAME=VT_160722_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006303_1 Sex:M | Treatment:placebo SampleID=50846; RAW_FILE_NAME=VT_160722_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001797_1 Sex:M | Treatment:placebo SampleID=90222; RAW_FILE_NAME=VT_160722_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000570_1 Sex:M | Treatment:placebo SampleID=90222; RAW_FILE_NAME=VT_160722_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001903_1 Sex:M | Treatment:81mg SampleID=90457; RAW_FILE_NAME=VT_160722_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106104_1 Sex:M | Treatment:81mg SampleID=90457; RAW_FILE_NAME=VT_160722_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001948_1 Sex:M | Treatment:81mg SampleID=90828; RAW_FILE_NAME=VT_160722_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006920_1 Sex:M | Treatment:81mg SampleID=90828; RAW_FILE_NAME=VT_160722_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001979_1 Sex:M | Treatment:81mg SampleID=91065; RAW_FILE_NAME=VT_160722_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106822_1 Sex:M | Treatment:81mg SampleID=91065; RAW_FILE_NAME=VT_160722_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002080_1 Sex:F | Treatment:placebo SampleID=71186; RAW_FILE_NAME=VT_160722_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001260_1 Sex:F | Treatment:placebo SampleID=71186; RAW_FILE_NAME=VT_160722_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106422_1 Sex:M | Treatment:placebo SampleID=30901; RAW_FILE_NAME=VT_160722_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005791_1 Sex:M | Treatment:placebo SampleID=30901; RAW_FILE_NAME=VT_160722_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_7b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160722_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_8a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160723_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000606_1 Sex:F | Treatment:81mg SampleID=40182; RAW_FILE_NAME=VT_160723_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001426_1 Sex:F | Treatment:81mg SampleID=40182; RAW_FILE_NAME=VT_160723_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001756_1 Sex:F | Treatment:81mg SampleID=80759; RAW_FILE_NAME=VT_160723_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105980_1 Sex:F | Treatment:81mg SampleID=80759; RAW_FILE_NAME=VT_160723_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001828_1 Sex:M | Treatment:81mg SampleID=81255; RAW_FILE_NAME=VT_160723_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000533_1 Sex:M | Treatment:81mg SampleID=81255; RAW_FILE_NAME=VT_160723_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001907_1 Sex:M | Treatment:placebo SampleID=90480; RAW_FILE_NAME=VT_160723_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015852_1 Sex:M | Treatment:placebo SampleID=90480; RAW_FILE_NAME=VT_160723_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001954_1 Sex:M | Treatment:325mg SampleID=90883; RAW_FILE_NAME=VT_160723_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006928_1 Sex:M | Treatment:325mg SampleID=90883; RAW_FILE_NAME=VT_160723_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001983_1 Sex:M | Treatment:81mg SampleID=91133; RAW_FILE_NAME=VT_160723_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106836_1 Sex:M | Treatment:81mg SampleID=91133; RAW_FILE_NAME=VT_160723_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002091_1 Sex:M | Treatment:81mg SampleID=71265; RAW_FILE_NAME=VT_160723_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000228_1 Sex:M | Treatment:81mg SampleID=71265; RAW_FILE_NAME=VT_160723_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000661_1 Sex:M | Treatment:placebo SampleID=40542; RAW_FILE_NAME=VT_160723_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000662_1 Sex:M | Treatment:placebo SampleID=40542; RAW_FILE_NAME=VT_160723_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001830_1 Sex:M | Treatment:325mg SampleID=81266; RAW_FILE_NAME=VT_160723_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006966_1 Sex:M | Treatment:325mg SampleID=81266; RAW_FILE_NAME=VT_160723_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001959_1 Sex:M | Treatment:81mg SampleID=90930; RAW_FILE_NAME=VT_160723_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006977_1 Sex:M | Treatment:81mg SampleID=90930; RAW_FILE_NAME=VT_160723_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_8b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160723_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_9a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160725_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002095_1 Sex:M | Treatment:81mg SampleID=71344; RAW_FILE_NAME=VT_160725_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015913_1 Sex:M | Treatment:81mg SampleID=71344; RAW_FILE_NAME=VT_160725_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002164_1 Sex:F | Treatment:81mg SampleID=61354; RAW_FILE_NAME=VT_160725_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006377_1 Sex:F | Treatment:81mg SampleID=61354; RAW_FILE_NAME=VT_160725_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002208_1 Sex:F | Treatment:325mg SampleID=70029; RAW_FILE_NAME=VT_160725_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001317_1 Sex:F | Treatment:325mg SampleID=70029; RAW_FILE_NAME=VT_160725_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002312_1 Sex:F | Treatment:81mg SampleID=70174; RAW_FILE_NAME=VT_160725_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001342_1 Sex:F | Treatment:81mg SampleID=70174; RAW_FILE_NAME=VT_160725_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002452_1 Sex:M | Treatment:placebo SampleID=50396; RAW_FILE_NAME=VT_160725_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006195_1 Sex:M | Treatment:placebo SampleID=50396; RAW_FILE_NAME=VT_160725_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002528_1 Sex:M | Treatment:81mg SampleID=50745; RAW_FILE_NAME=VT_160725_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000707_1 Sex:M | Treatment:81mg SampleID=50745; RAW_FILE_NAME=VT_160725_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002563_1 Sex:M | Treatment:placebo SampleID=51263; RAW_FILE_NAME=VT_160725_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006299_1 Sex:M | Treatment:placebo SampleID=51263; RAW_FILE_NAME=VT_160725_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002638_1 Sex:M | Treatment:325mg SampleID=60768; RAW_FILE_NAME=VT_160725_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001725_1 Sex:M | Treatment:325mg SampleID=60768; RAW_FILE_NAME=VT_160725_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003330_1 Sex:F | Treatment:81mg SampleID=20406; RAW_FILE_NAME=VT_160725_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005493_1 Sex:F | Treatment:81mg SampleID=20406; RAW_FILE_NAME=VT_160725_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002097_1 Sex:F | Treatment:325mg SampleID=71399; RAW_FILE_NAME=VT_160725_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006745_1 Sex:F | Treatment:325mg SampleID=71399; RAW_FILE_NAME=VT_160725_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_9b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160725_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_10a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160726_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002098_1 Sex:F | Treatment:81mg SampleID=71401; RAW_FILE_NAME=VT_160726_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106609_1 Sex:F | Treatment:81mg SampleID=71401; RAW_FILE_NAME=VT_160726_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002174_1 Sex:F | Treatment:81mg SampleID=61477; RAW_FILE_NAME=VT_160726_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106676_1 Sex:F | Treatment:81mg SampleID=61477; RAW_FILE_NAME=VT_160726_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002232_1 Sex:M | Treatment:325mg SampleID=70589; RAW_FILE_NAME=VT_160726_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106387_1 Sex:M | Treatment:325mg SampleID=70589; RAW_FILE_NAME=VT_160726_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002314_1 Sex:F | Treatment:81mg SampleID=70185; RAW_FILE_NAME=VT_160726_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001345_1 Sex:F | Treatment:81mg SampleID=70185; RAW_FILE_NAME=VT_160726_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002473_1 Sex:F | Treatment:placebo SampleID=50600; RAW_FILE_NAME=VT_160726_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015319_1 Sex:F | Treatment:placebo SampleID=50600; RAW_FILE_NAME=VT_160726_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002539_1 Sex:F | Treatment:81mg SampleID=50824; RAW_FILE_NAME=VT_160726_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000721_1 Sex:F | Treatment:81mg SampleID=50824; RAW_FILE_NAME=VT_160726_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002578_1 Sex:F | Treatment:placebo SampleID=51364; RAW_FILE_NAME=VT_160726_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105854_1 Sex:F | Treatment:placebo SampleID=51364; RAW_FILE_NAME=VT_160726_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002662_1 Sex:F | Treatment:placebo SampleID=60410; RAW_FILE_NAME=VT_160726_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006364_1 Sex:F | Treatment:placebo SampleID=60410; RAW_FILE_NAME=VT_160726_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003342_1 Sex:M | Treatment:81mg SampleID=20529; RAW_FILE_NAME=VT_160726_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000470_1 Sex:M | Treatment:81mg SampleID=20529; RAW_FILE_NAME=VT_160726_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002147_1 Sex:M | Treatment:placebo SampleID=61196; RAW_FILE_NAME=VT_160726_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006465_1 Sex:M | Treatment:placebo SampleID=61196; RAW_FILE_NAME=VT_160726_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_10b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160726_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_11a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160727_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002160_1 Sex:M | Treatment:placebo SampleID=61332; RAW_FILE_NAME=VT_160727_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006543_1 Sex:M | Treatment:placebo SampleID=61332; RAW_FILE_NAME=VT_160727_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002192_1 Sex:M | Treatment:placebo SampleID=61590; RAW_FILE_NAME=VT_160727_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106696_1 Sex:M | Treatment:placebo SampleID=61590; RAW_FILE_NAME=VT_160727_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002246_1 Sex:M | Treatment:placebo SampleID=70714; RAW_FILE_NAME=VT_160727_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001391_1 Sex:M | Treatment:placebo SampleID=70714; RAW_FILE_NAME=VT_160727_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002371_1 Sex:M | Treatment:81mg SampleID=41442; RAW_FILE_NAME=VT_160727_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106219_1 Sex:M | Treatment:81mg SampleID=41442; RAW_FILE_NAME=VT_160727_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002499_1 Sex:F | Treatment:81mg SampleID=51039; RAW_FILE_NAME=VT_160727_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006335_1 Sex:F | Treatment:81mg SampleID=51039; RAW_FILE_NAME=VT_160727_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002553_1 Sex:M | Treatment:placebo SampleID=51195; RAW_FILE_NAME=VT_160727_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105825_1 Sex:M | Treatment:placebo SampleID=51195; RAW_FILE_NAME=VT_160727_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002605_1 Sex:F | Treatment:325mg SampleID=60241; RAW_FILE_NAME=VT_160727_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015408_1 Sex:F | Treatment:325mg SampleID=60241; RAW_FILE_NAME=VT_160727_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003327_1 Sex:F | Treatment:325mg SampleID=20360; RAW_FILE_NAME=VT_160727_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000451_1 Sex:F | Treatment:325mg SampleID=20360; RAW_FILE_NAME=VT_160727_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003356_1 Sex:F | Treatment:81mg SampleID=20620; RAW_FILE_NAME=VT_160727_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005633_1 Sex:F | Treatment:81mg SampleID=20620; RAW_FILE_NAME=VT_160727_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002197_1 Sex:F | Treatment:81mg SampleID=61624; RAW_FILE_NAME=VT_160727_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006512_1 Sex:F | Treatment:81mg SampleID=61624; RAW_FILE_NAME=VT_160727_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_11b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160727_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_12a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160728_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002251_1 Sex:M | Treatment:325mg SampleID=70736; RAW_FILE_NAME=VT_160728_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000002_1 Sex:M | Treatment:325mg SampleID=70736; RAW_FILE_NAME=VT_160728_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002431_1 Sex:M | Treatment:325mg SampleID=50229; RAW_FILE_NAME=VT_160728_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006293_1 Sex:M | Treatment:325mg SampleID=50229; RAW_FILE_NAME=VT_160728_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002505_1 Sex:M | Treatment:placebo SampleID=51094; RAW_FILE_NAME=VT_160728_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105811_1 Sex:M | Treatment:placebo SampleID=51094; RAW_FILE_NAME=VT_160728_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002562_1 Sex:M | Treatment:81mg SampleID=51252; RAW_FILE_NAME=VT_160728_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006371_1 Sex:M | Treatment:81mg SampleID=51252; RAW_FILE_NAME=VT_160728_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002618_1 Sex:M | Treatment:placebo SampleID=60599; RAW_FILE_NAME=VT_160728_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105644_1 Sex:M | Treatment:placebo SampleID=60599; RAW_FILE_NAME=VT_160728_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003329_1 Sex:M | Treatment:325mg SampleID=20382; RAW_FILE_NAME=VT_160728_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000453_1 Sex:M | Treatment:325mg SampleID=20382; RAW_FILE_NAME=VT_160728_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003360_1 Sex:M | Treatment:81mg SampleID=20652; RAW_FILE_NAME=VT_160728_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015135_1 Sex:M | Treatment:81mg SampleID=20652; RAW_FILE_NAME=VT_160728_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002271_1 Sex:F | Treatment:placebo SampleID=70870; RAW_FILE_NAME=VT_160728_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001402_1 Sex:F | Treatment:placebo SampleID=70870; RAW_FILE_NAME=VT_160728_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002508_1 Sex:M | Treatment:325mg SampleID=51107; RAW_FILE_NAME=VT_160728_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015185_1 Sex:M | Treatment:325mg SampleID=51107; RAW_FILE_NAME=VT_160728_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40002636_1 Sex:M | Treatment:placebo SampleID=60757; RAW_FILE_NAME=VT_160728_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105664_1 Sex:M | Treatment:placebo SampleID=60757; RAW_FILE_NAME=VT_160728_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_12b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160728_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_13a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160729_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003364_1 Sex:M | Treatment:placebo SampleID=20685; RAW_FILE_NAME=VT_160729_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005531_1 Sex:M | Treatment:placebo SampleID=20685; RAW_FILE_NAME=VT_160729_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003440_1 Sex:F | Treatment:81mg SampleID=20046; RAW_FILE_NAME=VT_160729_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000872_1 Sex:F | Treatment:81mg SampleID=20046; RAW_FILE_NAME=VT_160729_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003495_1 Sex:F | Treatment:81mg SampleID=11584; RAW_FILE_NAME=VT_160729_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000862_1 Sex:F | Treatment:81mg SampleID=11584; RAW_FILE_NAME=VT_160729_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003540_1 Sex:M | Treatment:325mg SampleID=10381; RAW_FILE_NAME=VT_160729_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005386_1 Sex:M | Treatment:325mg SampleID=10381; RAW_FILE_NAME=VT_160729_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003591_1 Sex:F | Treatment:placebo SampleID=11260; RAW_FILE_NAME=VT_160729_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015066_1 Sex:F | Treatment:placebo SampleID=11260; RAW_FILE_NAME=VT_160729_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003657_1 Sex:M | Treatment:81mg SampleID=21250; RAW_FILE_NAME=VT_160729_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005626_1 Sex:M | Treatment:81mg SampleID=21250; RAW_FILE_NAME=VT_160729_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003707_1 Sex:M | Treatment:325mg SampleID=21585; RAW_FILE_NAME=VT_160729_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105914_1 Sex:M | Treatment:325mg SampleID=21585; RAW_FILE_NAME=VT_160729_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003744_1 Sex:F | Treatment:325mg SampleID=21990; RAW_FILE_NAME=VT_160729_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005735_1 Sex:F | Treatment:325mg SampleID=21990; RAW_FILE_NAME=VT_160729_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003788_1 Sex:F | Treatment:325mg SampleID=30495; RAW_FILE_NAME=VT_160729_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015590_1 Sex:F | Treatment:325mg SampleID=30495; RAW_FILE_NAME=VT_160729_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003365_1 Sex:F | Treatment:81mg SampleID=20696; RAW_FILE_NAME=VT_160729_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005557_1 Sex:F | Treatment:81mg SampleID=20696; RAW_FILE_NAME=VT_160729_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_13b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160729_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_14a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160730_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003373_1 Sex:M | Treatment:325mg SampleID=20775; RAW_FILE_NAME=VT_160730_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005534_1 Sex:M | Treatment:325mg SampleID=20775; RAW_FILE_NAME=VT_160730_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003451_1 Sex:M | Treatment:81mg SampleID=20136; RAW_FILE_NAME=VT_160730_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000422_1 Sex:M | Treatment:81mg SampleID=20136; RAW_FILE_NAME=VT_160730_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003509_1 Sex:M | Treatment:81mg SampleID=10056; RAW_FILE_NAME=VT_160730_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000745_1 Sex:M | Treatment:81mg SampleID=10056; RAW_FILE_NAME=VT_160730_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003548_1 Sex:M | Treatment:325mg SampleID=10416; RAW_FILE_NAME=VT_160730_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015927_1 Sex:M | Treatment:325mg SampleID=10416; RAW_FILE_NAME=VT_160730_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003596_1 Sex:M | Treatment:placebo SampleID=11316; RAW_FILE_NAME=VT_160730_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106273_1 Sex:M | Treatment:placebo SampleID=11316; RAW_FILE_NAME=VT_160730_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003658_1 Sex:M | Treatment:placebo SampleID=21260; RAW_FILE_NAME=VT_160730_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105864_1 Sex:M | Treatment:placebo SampleID=21260; RAW_FILE_NAME=VT_160730_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003709_1 Sex:F | Treatment:placebo SampleID=21609; RAW_FILE_NAME=VT_160730_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105916_1 Sex:F | Treatment:placebo SampleID=21609; RAW_FILE_NAME=VT_160730_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003756_1 Sex:F | Treatment:placebo SampleID=22105; RAW_FILE_NAME=VT_160730_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005758_1 Sex:F | Treatment:placebo SampleID=22105; RAW_FILE_NAME=VT_160730_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003801_1 Sex:F | Treatment:81mg SampleID=30700; RAW_FILE_NAME=VT_160730_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105622_1 Sex:F | Treatment:81mg SampleID=30700; RAW_FILE_NAME=VT_160730_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003377_1 Sex:M | Treatment:325mg SampleID=20821; RAW_FILE_NAME=VT_160730_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000289_1 Sex:M | Treatment:325mg SampleID=20821; RAW_FILE_NAME=VT_160730_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_14b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160730_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_15a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160731_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003434_1 Sex:M | Treatment:325mg SampleID=20013; RAW_FILE_NAME=VT_160731_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000868_1 Sex:M | Treatment:325mg SampleID=20013; RAW_FILE_NAME=VT_160731_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003464_1 Sex:M | Treatment:placebo SampleID=11349; RAW_FILE_NAME=VT_160731_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106280_1 Sex:M | Treatment:placebo SampleID=11349; RAW_FILE_NAME=VT_160731_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003511_1 Sex:M | Treatment:325mg SampleID=10067; RAW_FILE_NAME=VT_160731_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000746_1 Sex:M | Treatment:325mg SampleID=10067; RAW_FILE_NAME=VT_160731_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003554_1 Sex:M | Treatment:placebo SampleID=10506; RAW_FILE_NAME=VT_160731_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005350_1 Sex:M | Treatment:placebo SampleID=10506; RAW_FILE_NAME=VT_160731_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003620_1 Sex:M | Treatment:81mg SampleID=10910; RAW_FILE_NAME=VT_160731_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005411_1 Sex:M | Treatment:81mg SampleID=10910; RAW_FILE_NAME=VT_160731_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003675_1 Sex:M | Treatment:325mg SampleID=21383; RAW_FILE_NAME=VT_160731_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015617_1 Sex:M | Treatment:325mg SampleID=21383; RAW_FILE_NAME=VT_160731_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003716_1 Sex:M | Treatment:placebo SampleID=21700; RAW_FILE_NAME=VT_160731_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105926_1 Sex:M | Treatment:placebo SampleID=21700; RAW_FILE_NAME=VT_160731_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003760_1 Sex:M | Treatment:placebo SampleID=30036; RAW_FILE_NAME=VT_160731_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001007_1 Sex:M | Treatment:placebo SampleID=30036; RAW_FILE_NAME=VT_160731_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003821_1 Sex:M | Treatment:81mg SampleID=30945; RAW_FILE_NAME=VT_160731_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015625_1 Sex:M | Treatment:81mg SampleID=30945; RAW_FILE_NAME=VT_160731_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003467_1 Sex:M | Treatment:325mg SampleID=11350; RAW_FILE_NAME=VT_160731_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005496_1 Sex:M | Treatment:325mg SampleID=11350; RAW_FILE_NAME=VT_160731_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_15b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160731_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_16a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160801_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003519_1 Sex:F | Treatment:325mg SampleID=10135; RAW_FILE_NAME=VT_160801_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000757_1 Sex:F | Treatment:325mg SampleID=10135; RAW_FILE_NAME=VT_160801_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003573_1 Sex:M | Treatment:placebo SampleID=11079; RAW_FILE_NAME=VT_160801_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106772_1 Sex:M | Treatment:placebo SampleID=11079; RAW_FILE_NAME=VT_160801_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003623_1 Sex:M | Treatment:placebo SampleID=10943; RAW_FILE_NAME=VT_160801_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005393_1 Sex:M | Treatment:placebo SampleID=10943; RAW_FILE_NAME=VT_160801_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003678_1 Sex:F | Treatment:placebo SampleID=21407; RAW_FILE_NAME=VT_160801_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005592_1 Sex:F | Treatment:placebo SampleID=21407; RAW_FILE_NAME=VT_160801_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003732_1 Sex:M | Treatment:placebo SampleID=21866; RAW_FILE_NAME=VT_160801_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105511_1 Sex:M | Treatment:placebo SampleID=21866; RAW_FILE_NAME=VT_160801_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003777_1 Sex:M | Treatment:81mg SampleID=30339; RAW_FILE_NAME=VT_160801_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105573_1 Sex:M | Treatment:81mg SampleID=30339; RAW_FILE_NAME=VT_160801_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005286_1 Sex:M | Treatment:325mg SampleID=10640; RAW_FILE_NAME=VT_160801_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005280_1 Sex:M | Treatment:325mg SampleID=10640; RAW_FILE_NAME=VT_160801_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003526_1 Sex:M | Treatment:81mg SampleID=10179; RAW_FILE_NAME=VT_160801_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000763_1 Sex:M | Treatment:81mg SampleID=10179; RAW_FILE_NAME=VT_160801_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003630_1 Sex:M | Treatment:placebo SampleID=21014; RAW_FILE_NAME=VT_160801_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000315_1 Sex:M | Treatment:placebo SampleID=21014; RAW_FILE_NAME=VT_160801_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003736_1 Sex:M | Treatment:placebo SampleID=21901; RAW_FILE_NAME=VT_160801_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105517_1 Sex:M | Treatment:placebo SampleID=21901; RAW_FILE_NAME=VT_160801_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_16b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160801_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_17a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160802_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005288_1 Sex:M | Treatment:325mg SampleID=10190; RAW_FILE_NAME=VT_160802_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40003151_1 Sex:M | Treatment:325mg SampleID=10190; RAW_FILE_NAME=VT_160802_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005537_1 Sex:F | Treatment:81mg SampleID=20911; RAW_FILE_NAME=VT_160802_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005521_1 Sex:F | Treatment:81mg SampleID=20911; RAW_FILE_NAME=VT_160802_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005754_1 Sex:F | Treatment:81mg SampleID=30181; RAW_FILE_NAME=VT_160802_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005739_1 Sex:F | Treatment:81mg SampleID=30181; RAW_FILE_NAME=VT_160802_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005903_1 Sex:M | Treatment:81mg SampleID=40070; RAW_FILE_NAME=VT_160802_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001413_1 Sex:M | Treatment:81mg SampleID=40070; RAW_FILE_NAME=VT_160802_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005917_1 Sex:M | Treatment:placebo SampleID=40127; RAW_FILE_NAME=VT_160802_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001419_1 Sex:M | Treatment:placebo SampleID=40127; RAW_FILE_NAME=VT_160802_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006067_1 Sex:M | Treatment:325mg SampleID=50677; RAW_FILE_NAME=VT_160802_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000697_1 Sex:M | Treatment:325mg SampleID=50677; RAW_FILE_NAME=VT_160802_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006145_1 Sex:M | Treatment:81mg SampleID=41880; RAW_FILE_NAME=VT_160802_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006159_1 Sex:M | Treatment:81mg SampleID=41880; RAW_FILE_NAME=VT_160802_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006320_1 Sex:F | Treatment:81mg SampleID=50813; RAW_FILE_NAME=VT_160802_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000718_1 Sex:F | Treatment:81mg SampleID=50813; RAW_FILE_NAME=VT_160802_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006499_1 Sex:M | Treatment:placebo SampleID=61387; RAW_FILE_NAME=VT_160802_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106668_1 Sex:M | Treatment:placebo SampleID=61387; RAW_FILE_NAME=VT_160802_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005333_1 Sex:M | Treatment:81mg SampleID=10550; RAW_FILE_NAME=VT_160802_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106705_1 Sex:M | Treatment:81mg SampleID=10550; RAW_FILE_NAME=VT_160802_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_17b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160802_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_18a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160803_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005368_1 Sex:F | Treatment:325mg SampleID=10450; RAW_FILE_NAME=VT_160803_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005384_1 Sex:F | Treatment:325mg SampleID=10450; RAW_FILE_NAME=VT_160803_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005622_1 Sex:M | Treatment:placebo SampleID=21249; RAW_FILE_NAME=VT_160803_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005604_1 Sex:M | Treatment:placebo SampleID=21249; RAW_FILE_NAME=VT_160803_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005782_1 Sex:M | Treatment:325mg SampleID=21710; RAW_FILE_NAME=VT_160803_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005765_1 Sex:M | Treatment:325mg SampleID=21710; RAW_FILE_NAME=VT_160803_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005905_1 Sex:F | Treatment:81mg SampleID=40149; RAW_FILE_NAME=VT_160803_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001423_1 Sex:F | Treatment:81mg SampleID=40149; RAW_FILE_NAME=VT_160803_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005918_1 Sex:F | Treatment:placebo SampleID=40081; RAW_FILE_NAME=VT_160803_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001415_1 Sex:F | Treatment:placebo SampleID=40081; RAW_FILE_NAME=VT_160803_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006078_1 Sex:M | Treatment:placebo SampleID=41385; RAW_FILE_NAME=VT_160803_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106214_1 Sex:M | Treatment:placebo SampleID=41385; RAW_FILE_NAME=VT_160803_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006150_1 Sex:F | Treatment:placebo SampleID=50666; RAW_FILE_NAME=VT_160803_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000695_1 Sex:F | Treatment:placebo SampleID=50666; RAW_FILE_NAME=VT_160803_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006362_1 Sex:M | Treatment:81mg SampleID=61297; RAW_FILE_NAME=VT_160803_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106654_1 Sex:M | Treatment:81mg SampleID=61297; RAW_FILE_NAME=VT_160803_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006562_1 Sex:F | Treatment:81mg SampleID=80254; RAW_FILE_NAME=VT_160803_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000265_1 Sex:F | Treatment:81mg SampleID=80254; RAW_FILE_NAME=VT_160803_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005406_1 Sex:F | Treatment:81mg SampleID=11180; RAW_FILE_NAME=VT_160803_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000837_1 Sex:F | Treatment:81mg SampleID=11180; RAW_FILE_NAME=VT_160803_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_18b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160803_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_19a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160804_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005501_1 Sex:M | Treatment:placebo SampleID=20079; RAW_FILE_NAME=VT_160804_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000879_1 Sex:M | Treatment:placebo SampleID=20079; RAW_FILE_NAME=VT_160804_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005751_1 Sex:M | Treatment:81mg SampleID=30104; RAW_FILE_NAME=VT_160804_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001017_1 Sex:M | Treatment:81mg SampleID=30104; RAW_FILE_NAME=VT_160804_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005812_1 Sex:M | Treatment:325mg SampleID=30250; RAW_FILE_NAME=VT_160804_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106625_1 Sex:M | Treatment:325mg SampleID=30250; RAW_FILE_NAME=VT_160804_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005906_1 Sex:M | Treatment:325mg SampleID=40193; RAW_FILE_NAME=VT_160804_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001429_1 Sex:M | Treatment:325mg SampleID=40193; RAW_FILE_NAME=VT_160804_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006003_1 Sex:M | Treatment:placebo SampleID=40373; RAW_FILE_NAME=VT_160804_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000633_1 Sex:M | Treatment:placebo SampleID=40373; RAW_FILE_NAME=VT_160804_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006104_1 Sex:F | Treatment:placebo SampleID=41172; RAW_FILE_NAME=VT_160804_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006094_1 Sex:F | Treatment:placebo SampleID=41172; RAW_FILE_NAME=VT_160804_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006183_1 Sex:F | Treatment:325mg SampleID=60623; RAW_FILE_NAME=VT_160804_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015382_1 Sex:F | Treatment:325mg SampleID=60623; RAW_FILE_NAME=VT_160804_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006442_1 Sex:F | Treatment:placebo SampleID=60386; RAW_FILE_NAME=VT_160804_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006426_1 Sex:F | Treatment:placebo SampleID=60386; RAW_FILE_NAME=VT_160804_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006607_1 Sex:M | Treatment:placebo SampleID=71276; RAW_FILE_NAME=VT_160804_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000230_1 Sex:M | Treatment:placebo SampleID=71276; RAW_FILE_NAME=VT_160804_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005753_1 Sex:M | Treatment:placebo SampleID=30160; RAW_FILE_NAME=VT_160804_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005738_1 Sex:M | Treatment:placebo SampleID=30160; RAW_FILE_NAME=VT_160804_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_19b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160804_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_20a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160805_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005843_1 Sex:F | Treatment:325mg SampleID=30137; RAW_FILE_NAME=VT_160805_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005829_1 Sex:F | Treatment:325mg SampleID=30137; RAW_FILE_NAME=VT_160805_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005909_1 Sex:M | Treatment:325mg SampleID=30462; RAW_FILE_NAME=VT_160805_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105589_1 Sex:M | Treatment:325mg SampleID=30462; RAW_FILE_NAME=VT_160805_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006035_1 Sex:F | Treatment:81mg SampleID=40968; RAW_FILE_NAME=VT_160805_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001489_1 Sex:F | Treatment:81mg SampleID=40968; RAW_FILE_NAME=VT_160805_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006117_1 Sex:F | Treatment:placebo SampleID=50207; RAW_FILE_NAME=VT_160805_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006133_1 Sex:F | Treatment:placebo SampleID=50207; RAW_FILE_NAME=VT_160805_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006251_1 Sex:M | Treatment:325mg SampleID=50139; RAW_FILE_NAME=VT_160805_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001571_1 Sex:M | Treatment:325mg SampleID=50139; RAW_FILE_NAME=VT_160805_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006484_1 Sex:F | Treatment:placebo SampleID=61073; RAW_FILE_NAME=VT_160805_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006509_1 Sex:F | Treatment:placebo SampleID=61073; RAW_FILE_NAME=VT_160805_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006620_1 Sex:F | Treatment:325mg SampleID=61657; RAW_FILE_NAME=VT_160805_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006598_1 Sex:F | Treatment:325mg SampleID=61657; RAW_FILE_NAME=VT_160805_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005899_1 Sex:F | Treatment:placebo SampleID=31060; RAW_FILE_NAME=VT_160805_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015704_1 Sex:F | Treatment:placebo SampleID=31060; RAW_FILE_NAME=VT_160805_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006066_1 Sex:M | Treatment:81mg SampleID=41622; RAW_FILE_NAME=VT_160805_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106246_1 Sex:M | Treatment:81mg SampleID=41622; RAW_FILE_NAME=VT_160805_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006289_1 Sex:M | Treatment:325mg SampleID=50947; RAW_FILE_NAME=VT_160805_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006275_1 Sex:M | Treatment:325mg SampleID=50947; RAW_FILE_NAME=VT_160805_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_20b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160805_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_21a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160808_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006824_1 Sex:M | Treatment:81mg SampleID=41117; RAW_FILE_NAME=VT_160808_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40016034_1 Sex:M | Treatment:81mg SampleID=41117; RAW_FILE_NAME=VT_160808_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007061_1 Sex:M | Treatment:325mg SampleID=91368; RAW_FILE_NAME=VT_160808_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015207_1 Sex:M | Treatment:325mg SampleID=91368; RAW_FILE_NAME=VT_160808_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022389_1 Sex:M | Treatment:325mg SampleID=50363; RAW_FILE_NAME=VT_160808_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106524_1 Sex:M | Treatment:325mg SampleID=50363; RAW_FILE_NAME=VT_160808_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022729_1 Sex:M | Treatment:81mg SampleID=60130; RAW_FILE_NAME=VT_160808_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400105726_1 Sex:M | Treatment:81mg SampleID=60130; RAW_FILE_NAME=VT_160808_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022884_1 Sex:M | Treatment:placebo SampleID=40452; RAW_FILE_NAME=VT_160808_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005979_1 Sex:M | Treatment:placebo SampleID=40452; RAW_FILE_NAME=VT_160808_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006829_1 Sex:M | Treatment:81mg SampleID=30328; RAW_FILE_NAME=VT_160808_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006834_1 Sex:M | Treatment:81mg SampleID=30328; RAW_FILE_NAME=VT_160808_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40014515_1 Sex:M | Treatment:81mg SampleID=61398; RAW_FILE_NAME=VT_160808_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106670_1 Sex:M | Treatment:81mg SampleID=61398; RAW_FILE_NAME=VT_160808_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022463_1 Sex:M | Treatment:325mg SampleID=60107; RAW_FILE_NAME=VT_160808_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015418_1 Sex:M | Treatment:325mg SampleID=60107; RAW_FILE_NAME=VT_160808_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022736_1 Sex:F | Treatment:325mg SampleID=70365; RAW_FILE_NAME=VT_160808_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006699_1 Sex:F | Treatment:325mg SampleID=70365; RAW_FILE_NAME=VT_160808_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022886_1 Sex:F | Treatment:81mg SampleID=41879; RAW_FILE_NAME=VT_160808_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 400106480_1 Sex:F | Treatment:81mg SampleID=41879; RAW_FILE_NAME=VT_160808_M198_121 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_21b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160808_M198_127 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_22a_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160809_M198_001 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006904_1 Sex:F | Treatment:placebo SampleID=80781; RAW_FILE_NAME=VT_160809_M198_007 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001158_1 Sex:F | Treatment:placebo SampleID=80781; RAW_FILE_NAME=VT_160809_M198_013 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40014518_1 Sex:F | Treatment:81mg SampleID=40474; RAW_FILE_NAME=VT_160809_M198_019 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005944_1 Sex:F | Treatment:81mg SampleID=40474; RAW_FILE_NAME=VT_160809_M198_025 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022474_1 Sex:M | Treatment:81mg SampleID=50161; RAW_FILE_NAME=VT_160809_M198_031 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001573_1 Sex:M | Treatment:81mg SampleID=50161; RAW_FILE_NAME=VT_160809_M198_037 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022743_1 Sex:M | Treatment:placebo SampleID=30282; RAW_FILE_NAME=VT_160809_M198_043 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015575_1 Sex:M | Treatment:placebo SampleID=30282; RAW_FILE_NAME=VT_160809_M198_049 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022904_1 Sex:M | Treatment:325mg SampleID=80546; RAW_FILE_NAME=VT_160809_M198_055 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001194_1 Sex:M | Treatment:325mg SampleID=80546; RAW_FILE_NAME=VT_160809_M198_061 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40006953_1 Sex:F | Treatment:325mg SampleID=81009; RAW_FILE_NAME=VT_160809_M198_067 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015520_1 Sex:F | Treatment:325mg SampleID=81009; RAW_FILE_NAME=VT_160809_M198_073 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40021544_1 Sex:F | Treatment:325mg SampleID=90031; RAW_FILE_NAME=VT_160809_M198_079 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001038_1 Sex:F | Treatment:325mg SampleID=90031; RAW_FILE_NAME=VT_160809_M198_085 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022479_1 Sex:M | Treatment:325mg SampleID=20226; RAW_FILE_NAME=VT_160809_M198_091 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40005470_1 Sex:M | Treatment:325mg SampleID=20226; RAW_FILE_NAME=VT_160809_M198_097 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022874_1 Sex:F | Treatment:placebo SampleID=21306; RAW_FILE_NAME=VT_160809_M198_103 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40000953_1 Sex:F | Treatment:placebo SampleID=21306; RAW_FILE_NAME=VT_160809_M198_109 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022906_1 Sex:M | Treatment:81mg SampleID=81064; RAW_FILE_NAME=VT_160809_M198_115 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001179_1 Sex:M | Treatment:81mg SampleID=81064; RAW_FILE_NAME=VT_160809_M198_121 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007050_1 Sex:F | Treatment:placebo SampleID=91199; RAW_FILE_NAME=VT_160809_M198_127 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40007067_1 Sex:F | Treatment:placebo SampleID=91199; RAW_FILE_NAME=VT_160809_M198_133 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022480_1 Sex:F | Treatment:81mg SampleID=70231; RAW_FILE_NAME=VT_160809_M198_139 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40001351_1 Sex:F | Treatment:81mg SampleID=70231; RAW_FILE_NAME=VT_160809_M198_145 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40022907_1 Sex:M | Treatment:placebo SampleID=81086; RAW_FILE_NAME=VT_160809_M198_151 SUBJECT_SAMPLE_FACTORS Plasma Study Sample 40015816_1 Sex:M | Treatment:placebo SampleID=81086; RAW_FILE_NAME=VT_160809_M198_157 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_22b_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160809_M198_163 SUBJECT_SAMPLE_FACTORS Quality Control q3June2014_22c_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160809_M198_169 SUBJECT_SAMPLE_FACTORS Quality Control nist2_1 Sex:NA | Treatment:NA SampleID=NA; RAW_FILE_NAME=VT_160809_M198_175 #COLLECTION CO:COLLECTION_SUMMARY Blood plasma samples were collected from non-fasting participants in the CO:COLLECTION_SUMMARY Aspirin/Folate Polyp Prevention Study at enrollment (baseline) and after three CO:COLLECTION_SUMMARY years of study treatment. Blood samples were collected in tubes containing EDTA CO:COLLECTION_SUMMARY and after centrifugation aliquots of plasma were transferred to 1.8ml freezer CO:COLLECTION_SUMMARY tubes and stored frozen at -20C or lower. The samples were shipped on dry ice CO:COLLECTION_SUMMARY from the clinical centers to the Dartmouth biorepository storage facility (for CO:COLLECTION_SUMMARY storage at -70C) and subsequently to the metabolomics analysis lab at Emory CO:COLLECTION_SUMMARY University. CO:SAMPLE_TYPE Blood (plasma) CO:STORAGE_CONDITIONS Described in summary #TREATMENT TR:TREATMENT_SUMMARY Samples were received frozen in aliquouts of <250uL. Prior to analysis, samples TR:TREATMENT_SUMMARY were thawed and prepared for HRM analysis using the standard protocols described TR:TREATMENT_SUMMARY in the Sample Preparation section. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Samples were prepared for metabolomics analysis using established SP:SAMPLEPREP_SUMMARY methods(Johnson et al. (2010). Analyst; Go et al. (2015). Tox Sci). Prior to SP:SAMPLEPREP_SUMMARY analysis, plasma aliquots were removed from storage at -80 degrees C and thawed SP:SAMPLEPREP_SUMMARY on ice. Each cryotube was then vortexed briefly to ensure homogeneity, and 50 SP:SAMPLEPREP_SUMMARY microliters was transferred to a clean microfuge tube. Immediately after, the SP:SAMPLEPREP_SUMMARY plasma was treated with 100 microliters of ice-cold LC-MS grade acetonitrile SP:SAMPLEPREP_SUMMARY (Sigma Aldrich) containing 2.5 microliters of internal standard solution with SP:SAMPLEPREP_SUMMARY eight stable isotopic chemicals selected to cover a range of chemical SP:SAMPLEPREP_SUMMARY properties. Following addition of acetonitrile, urine was equilibrated for 30 SP:SAMPLEPREP_SUMMARY min on ice, upon which precipitated proteins were removed by centrifuge SP:SAMPLEPREP_SUMMARY (14,000rpm at 4 degrees C for 10 min). The resulting supernatant (100 SP:SAMPLEPREP_SUMMARY microliters) was removed, added to a low volume autosampler vial and maintained SP:SAMPLEPREP_SUMMARY at 4 degrees C until analysis (<22 h). SP:SAMPLEPREP_PROTOCOL_ID HRM_SP_082016_01 SP:SAMPLEPREP_PROTOCOL_FILENAME EmoryUniversity_HRM_SP_082016_01.pdf SP:SAMPLEPREP_PROTOCOL_COMMENTS Date effective: 30 July 2016 SP:PROCESSING_STORAGE_CONDITIONS On ice SP:EXTRACTION_METHOD 2:1 acetonitrile: sample followed by vortexing and centrifugation SP:EXTRACT_STORAGE 4℃ #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY The HILIC column is operated parallel to reverse phase column for simultaneous CH:CHROMATOGRAPHY_SUMMARY analytical separation and column flushing through the use of a dual head HPLC CH:CHROMATOGRAPHY_SUMMARY pump equipped with 10-port and 6-port switching valves. During operation of CH:CHROMATOGRAPHY_SUMMARY HILIC separation method, the MS is operated in positive ion mode and 10 CH:CHROMATOGRAPHY_SUMMARY microliters of sample is injected onto the HILIC column while the reverse phase CH:CHROMATOGRAPHY_SUMMARY column is flushing with wash solution. Flow rate is maintained at 0.35 mL/min CH:CHROMATOGRAPHY_SUMMARY until 2 min, increased to 0.4 mL/min at 6 min and held for 4 min. Solvent A is CH:CHROMATOGRAPHY_SUMMARY 100% LC-MS grade water, solvent B is 100% LC-MS grade acetonitrile and solvent C CH:CHROMATOGRAPHY_SUMMARY is 2% formic acid (v/v) in LC-MS grade water. Initial mobile phase conditions CH:CHROMATOGRAPHY_SUMMARY are 25% A, 70% B, 5% C hold for 2 min, with linear gradient to 75% A, 20% B, 5% CH:CHROMATOGRAPHY_SUMMARY C at 6 min, hold for 4 min, resulting in a total analytical run time of 10 min. CH:CHROMATOGRAPHY_SUMMARY During the flushing phase (reverse phase analytical separation), the HILIC CH:CHROMATOGRAPHY_SUMMARY column is equilibrated with a wash solution of 25% A, 70% B, 5% C. CH:CHROMATOGRAPHY_TYPE HILIC CH:INSTRUMENT_NAME Dionex UltiMate 3000 CH:COLUMN_NAME Thermo Fisher Accucore HILIC with guard cartridge(50x2.1mm 2.6u) CH:COLUMN_TEMPERATURE 60C CH:METHODS_FILENAME 20160120_posHILIC120kres10min_ESI_c18poswash_acrore.meth CH:SOLVENT_A LC-MS grade water CH:SOLVENT_B LC-MS grade acetonitrile CH:METHODS_ID 2% formic acid in LC-MS grade water CH:SAMPLE_INJECTION 10 uL CH:ANALYTICAL_TIME 10 min CH:SAMPLE_LOOP_SIZE 15 uL CH:SAMPLE_SYRINGE_SIZE 100 uL CH:CHROMATOGRAPHY_COMMENTS Triplicate injections for each chromatography mode #ANALYSIS AN:ANALYSIS_TYPE MS AN:LABORATORY_NAME Clinical Biomarkers Laboratory AN:OPERATOR_NAME ViLinh Tran AN:DETECTOR_TYPE Orbitrap AN:SOFTWARE_VERSION Xcalibur 3.0.63 AN:ACQUISITION_DATE 7/15/16-8/9/16 AN:ANALYSIS_PROTOCOL_FILE EmoryUniversity_HRM_QEHF-MS_092017_10min_v2 AN:DATA_FORMAT Profile #MS MS:INSTRUMENT_NAME Thermo Q Exactive HF hybrid Orbitrap MS:INSTRUMENT_TYPE Orbitrap MS:MS_TYPE ESI MS:ION_MODE POSITIVE MS:MS_COMMENTS None MS:CAPILLARY_TEMPERATURE 250C MS:COLLISION_GAS N2 MS:DRY_GAS_FLOW 45 MS:DRY_GAS_TEMP 150C MS:MASS_ACCURACY < 3ppm MS:SPRAY_VOLTAGE 3500 MS:ACTIVATION_PARAMETER 5.00E+05 MS:ACTIVATION_TIME 118ms MS:INTERFACE_VOLTAGE S-Lens RF level= 55 MS:MS_RESULTS_FILE ST001423_AN002380_Results.txt UNITS:peak area Has m/z:Yes Has RT:Yes RT units:Seconds #END